{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:19:26Z","timestamp":1783988366884,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.ejmech.2011.04.016","type":"journal-article","created":{"date-parts":[[2011,4,18]],"date-time":"2011-04-18T23:05:28Z","timestamp":1303167928000},"page":"2917-2929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Anti-prion activities and drug-like potential of functionalized quinacrine analogs with basic phenyl residues at the 9-amino position"],"prefix":"10.1016","volume":"46","author":[{"given":"Thuy","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Sakasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Doh-ura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Lin","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2011.04.016_bib1","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1152\/physrev.00006.2009","article-title":"Prions: protein aggregation and infectious diseases","volume":"89","author":"Aguzzi","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2011.04.016_bib2","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1093\/brain\/awl150","article-title":"A\u00a0systematic review of prion therapeutics in experimental models","volume":"129","author":"Trevitt","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2011.04.016_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1871526510909010081","article-title":"Recent advances in prion chemotherapeutics","volume":"9","author":"Sim","year":"2009","journal-title":"Infect. Disord. Drug Targets"},{"key":"10.1016\/j.ejmech.2011.04.016_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/1871526510909010015","article-title":"Amyloidophilic compounds for prion diseases","volume":"9","author":"Teruya","year":"2009","journal-title":"Infect. Disord. Drug Targets"},{"key":"10.1016\/j.ejmech.2011.04.016_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrn1584","article-title":"Rational targeting for prion therapeutics","volume":"6","author":"Mallucci","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2011.04.016_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1126\/science.6801762","article-title":"Novel proteinacious infectious particles cause scrapie","volume":"216","author":"Prusiner","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2011.04.016_bib7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1212\/01.WNL.0000113764.35026.EF","article-title":"Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study","volume":"62","author":"Otto","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2011.04.016_bib8","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1212\/01.WNL.0000148596.15681.4D","article-title":"Compassionate use of quinacrine in Creutzfeldt\u2013Jakob disease fails to show significant effects","volume":"63","author":"Haik","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2011.04.016_bib9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000076350","article-title":"Results of quinacrine administration to patients with Creutzfeldt\u2013Jakob disease","volume":"17","author":"Nakajima","year":"2004","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.ejmech.2011.04.016_bib10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.surneu.2005.03.035","article-title":"Creutzfeldt\u2013Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine","volume":"64","author":"Martinez-Lage","year":"2005","journal-title":"Surg. Neurol."},{"key":"10.1016\/j.ejmech.2011.04.016_bib11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","article-title":"A\u00a0partially randomised patient preference trial to assess the safety and activity of quinacrine in human prion disease: the PRION-1 trial","volume":"8","author":"Collinge","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2011.04.016_bib12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0140-6736(82)90652-3","article-title":"Repeated suppression of Creutzfeldt\u2013Jakob disease with vidarabine","volume":"2","author":"Furlow","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2011.04.016_bib13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/infdis\/165.4.784","article-title":"Failure to ameliorate Creutzfeldt\u2013Jakob disease with amphotericin B therapy","volume":"165","author":"Masullo","year":"1992","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2011.04.016_bib14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/archneur.1983.04050080055010","article-title":"The effect of amantadine on arousal and EEG patterns in Creutzfeldt\u2013Jakob disease","volume":"40","author":"Terzano","year":"1983","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejmech.2011.04.016_bib15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1124\/dmd.105.008664","article-title":"Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4\/5 and its brain accumulation is limited by P-glycoprotein","volume":"34","author":"Huang","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2011.04.016_bib16","doi-asserted-by":"crossref","first-page":"e1000673","DOI":"10.1371\/journal.ppat.1000673","article-title":"Continuous quinacrine treatment results in the formation of drug-resistant prions","volume":"5","author":"Ghaemmaghami","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2011.04.016_bib17","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1073\/pnas.2627988100","article-title":"Potent inhibition of scrapie prion replication in cultured cells by bis-acridines","volume":"100","author":"May","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2011.04.016_bib18","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1471-4159.2006.03889.x","article-title":"Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments","volume":"98","author":"Klingenstein","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2011.04.016_bib19","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1016\/j.bmc.2008.05.060","article-title":"Antiprion activity of functionalized 9-aminoacridines related to quinacrine","volume":"16","author":"Nguyen Thi","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.04.016_bib20","series-title":"The Practice of Medicinal Chemistry","first-page":"445","article-title":"Substituent groups","author":"Bazzini","year":"2008"},{"key":"10.1016\/j.ejmech.2011.04.016_bib21","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1016\/S0968-0896(03)00521-2","article-title":"Inhibition of bovine plasma amine oxidase by 1,4-diamino-2-butenes and -2-butynes","volume":"11","author":"Jeon","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.04.016_bib22","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1021\/jm010308g","article-title":"Homodimeric tacrine congeners as acetylcholinesterase inhibitors","volume":"45","author":"Hu","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.04.016_bib23","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1016\/S0040-4020(98)00088-X","article-title":"New syntheses of indole phytoalexins and related compounds","volume":"54","author":"Kutschy","year":"1998","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2011.04.016_bib24","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1128\/jvi.74.10.4894-4897.2000","article-title":"Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation","volume":"74","author":"Doh-Ura","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2011.04.016_bib25","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1021\/jm060773j","article-title":"A\u00a0chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations","volume":"49","author":"Dollinger","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.04.016_bib26","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1021\/jm070688r","article-title":"New series of antiprion compounds: Pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation","volume":"50","author":"Kimata","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.04.016_bib27","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1248\/bpb.29.927","article-title":"Surface plasmon resonance analysis for the screening of anti-prion compounds","volume":"29","author":"Kawatake","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2011.04.016_bib28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jpba.2005.08.011","article-title":"Screening a library of potential prion therapeutics against cellular prion proteins and insights into their mode of biological activities by surface plasmon resonance","volume":"40","author":"Touil","year":"2006","journal-title":"J.\u00a0Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2011.04.016_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","article-title":"High throughput artificial membrane permeability assay for blood-brain barrier","volume":"38","author":"Di","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.04.016_bib30","series-title":"Drug-like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization","first-page":"122","article-title":"Blood\u2013brain barrier","author":"Kerns","year":"2008"},{"key":"10.1016\/j.ejmech.2011.04.016_bib31","first-page":"205","article-title":"Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood\u2013brain barrier","volume":"24","author":"Dohgu","year":"2004","journal-title":"Cell Mol. Biol."},{"key":"10.1016\/j.ejmech.2011.04.016_bib32","first-page":"C955","article-title":"Organic cation transport in rat choroid plexus cells studied by fluorescence microscopy","volume":"276","author":"Miller","year":"1999","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.ejmech.2011.04.016_bib33","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1128\/AAC.01112-08","article-title":"Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: correlation between antiprion activity and binding affinity","volume":"53","author":"Hosokawa-Muto","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2011.04.016_bib34","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/cmdc.201000217","article-title":"Improved 2,4-diarylthiazole-based antiprion agents: switching the sense of the amide group at C5 leads to an increase in potency","volume":"5","author":"Thompson","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2011.04.016_bib35","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm0612719","article-title":"Library Synthesis and screening: 2,4-diphenylthiazoles and 2,4-diphenyloxazoles as potential novel prion disease therapeutics","volume":"50","author":"Heal","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.04.016_bib36","doi-asserted-by":"crossref","first-page":"9836","DOI":"10.1073\/pnas.161274798","article-title":"Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease","volume":"98","author":"Korth","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2011.04.016_bib37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejps.2008.07.008","article-title":"Dimethoxyaurones: potent inhibitors of ABCG2 (breast cancer resistance protein)","volume":"35","author":"Sim","year":"2008","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523411003011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523411003011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:39:19Z","timestamp":1759325959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523411003011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0223523411003011"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2011.04.016","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-prion activities and drug-like potential of functionalized quinacrine analogs with basic phenyl residues at the 9-amino position","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2011.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}